We selected an antibody targeting the Wnt-binding site of GPC3 to construct a novel anti-GPC3 immunotoxin, which exhibited effective antitumor activity via PE toxin-mediated cytotoxicity and antibody fragment-mediated blocking of cancer signaling [3, 23]. The gene discussed is GPC3; the disease is cancer.